Published • loading... • Updated
Novartis Finalizes US Manufacturing and R&D Expansion Plan with Seventh New Facility
The new site is part of a $23 billion U.S. investment plan and will support domestic production of tablets, capsules and RNA therapies.
- On Thursday, Novartis announced it will build a 56,200-square-foot facility in Morrisville, North Carolina, to manufacture active pharmaceutical ingredients for solid dosage tablets, capsules, and RNA therapeutics.
- The project marks the company's seventh new facility announced within a year, advancing a $23 billion investment plan to establish end-to-end manufacturing in the United States.
- CEO Vas Narasimhan stated, "By building a connected, end-to-end footprint, we are strengthening our ability to locally develop, produce, and deliver medicines at scale, enabling timely access to innovation for patients in the U.S."
- The Morrisville site expands the company's North Carolina footprint to five facilities across three locations, complementing existing operations in Durham and Wake Counties.
- Beyond North Carolina, Novartis is developing additional research and manufacturing sites in California, Texas, and Florida, while expanding existing facilities in Indiana and New Jersey.
Insights by Ground AI
11 Articles
11 Articles
Novartis opens its seventh US site in Morrisville, North Carolina, dedicated to active ingredients and RNA therapies. This deployment is part of a $23 billion plan to produce locally all medicines for US patientsNovartis is expanding its production capacity in the United States, with the announcement of a new site in Morrisville, North Carolina. This plant will bring to seven the number of new sites planned under its $23 billion overseas investm…
Swiss pharma firm Novartis plans seventh US plant
Novartis is expanding its production capacity in the United States, with the announcement of a new site in Morrisville, North Carolina. This plant will bring to seven the number of new sites planned as part of its $23 billion investment plan.
·Bern, Switzerland
Read Full Article
Coverage Details
Total News Sources11
Leaning Left2Leaning Right1Center3Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 33%
C 50%
R 17%
Factuality
To view factuality data please Upgrade to Premium
